AbbVie 2012 Annual Report Download - page 68
Download and view the complete annual report
Please find page 68 of the 2012 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.-
1 -
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40
-
41
-
42
-
43
-
44
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
-
53
-
54
-
55
-
56
-
57
-
58 -
59 -
60 -
61 -
62 -
63 -
64 -
65 -
66 -
67 -
68 -
69 -
70 -
71 -
72 -
73 -
74 -
75 -
76 -
77 -
78 -
79
-
80
-
81
-
82
-
83
-
84
-
85
-
86
-
87
-
88
-
89
-
90
-
91
-
92
-
93
-
94
-
95
-
96
-
97
-
98
-
99
-
100
-
101
-
102
-
103
-
104
-
105
-
106
-
107
-
108
-
109
-
110
-
111
-
112
-
113
-
114
-
115
-
116
-
117
-
118
-
119
-
120
-
121
-
122
-
123
-
124
-
125
-
126
-
127
-
128
-
129
-
130
-
131
-
132
-
133
-
134
-
135
-
136
-
137
-
138
-
139
-
140
-
141
-
142
-
143
-
144
-
145
-
146
-
147
-
148
-
149
-
150
-
151
-
152
-
153
-
154
-
155
-
156
-
157
-
158
-
159
-
160
-
161
-
162
-
163
-
164
-
165
-
166
-
167
-
168
-
169
-
170
-
171
-
172
-
173
-
174
-
175
-
176
-
177
-
178
-
179
-
180
-
181
-
182
-
183
-
184
-
185
-
186
-
187
-
188
-
189
-
190
-
191
-
192
-
193
-
194
-
195
-
196
-
197
-
198
-
199
-
200
 |
 |
AbbVie Inc. and Subsidiaries
Combined Statements of Cash Flows
years ended December 31 (in millions) (brackets denote cash outflows) 2012 2011 2010
Cash flows from operating activities
Net earnings $ 5,275 $ 3,433 $ 4,178
Adjustments to reconcile earnings to net cash from operating activities:
Depreciation 525 508 476
Amortization of intangible assets 625 764 708
Stock-based compensation 187 163 167
Acquired in-process research and development 288 673 313
Other 66 ——
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable 223 (498) (60)
Inventories (203) (87) (73)
Prepaid expenses and other assets 90 (206) (38)
Accounts payable and other liabilities (731) 1,497 (695)
Cash flows from operating activities 6,345 6,247 4,976
Cash flows from investing activities
Acquisitions and investments, net of cash acquired (688) (273) (2,621)
Acquisitions of property and equipment (333) (356) (448)
Release of (deposit of) restricted funds — 1,870 (1,870)
Purchases of investment securities (2,550) (1,943) (93)
Sales of investment securities 1,153 1,255 1
Cash flows from investing activities (2,418) 553 (5,031)
Cash flows from financing activities
Proceeds from issuance of long-term debt 14,586 ——
Net change in short-term borrowings 1,000 ——
Other (151) (21) (32)
Net transactions with Abbott Laboratories, excluding noncash items (13,504) (6,762) 97
Cash flows from financing activities 1,931 (6,783) 65
Effect of exchange rate changes on cash and equivalents 16 ——
Net increase in cash and equivalents 5,874 17 10
Cash and equivalents, beginning of year 27 10 —
Cash and equivalents, end of year $ 5,901 $ 27 $ 10
The accompanying notes are an integral part of these combined financial statements.
62